Avrobio, Inc. operates as a bio-technology company. The Company develops step-change cell and gene therapies for the treatment of cancer and rare disease. Avrobio serves clients in the United States and Canada.

Current Report (Form 8-K | Period ending 2024-06-20)

Current Report (Amendment) (Form 8-K/A | Period ending 2024-06-14)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Avrobio Inc (AVRO US)

Current Report (Form 8-K | Period ending 2024-06-20)

Current Report (Amendment) (Form 8-K/A | Period ending 2024-06-14)

Current Report (Form 8-K | Period ending 2024-06-14)

Current Report (Form 8-K | Period ending 2024-06-11)

425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)